Form 4: BioDeisx Chief Accounting Officer Chris Vazquez Reports Stock Transactions
SEC Form 4 Filing
BioDeisx's Chief Accounting Officer, Chris Vazquez, reported the acquisition of 602 shares through restricted stock units and the subsequent sale of 203 shares to cover taxes.
Summary
- Chris Vazquez, the Chief Accounting Officer of BioDeisx, reported transactions involving the company's common stock.
- On November 8, 2024, Mr. Vazquez acquired 602 shares through the vesting of restricted stock units (RSUs).
- On November 11, 2024, 105 shares were sold at an average price of $1.3909 per share to cover taxes related to the vesting of RSUs.
- On November 12, 2024, an additional 98 shares were sold at an average price of $1.4008 per share for the same purpose.
- The sales were executed automatically by the Issuer's broker and the prices ranged from $1.36 to $1.43 per share across the two days.
- Following these transactions, Mr. Vazquez beneficially owns 11,587 shares of BioDeisx common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an officer, which is neither positive nor negative in itself. It is a neutral event.
Industry Context
This is a routine filing related to stock transactions by a company officer, which is common in publicly traded companies. It does not indicate any specific trend or event in the broader industry.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
- The transactions are related to the vesting of restricted stock units, which is a common form of compensation for executives in the biotechnology industry.
- The sale of shares to cover taxes is also a typical occurrence when RSUs vest.
Stakeholder Impact
- The transactions have a minor impact on the total outstanding shares of BioDeisx.
- The sales of shares by an officer may be viewed neutrally by investors as they are related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 11/08/2024 | Restricted stock units vested, resulting in the acquisition of 602 shares. |
| 11/11/2024 | 105 shares sold at an average price of $1.3909 to cover taxes. |
| 11/12/2024 | 98 shares sold at an average price of $1.4008 to cover taxes. |
| 11/13/2024 | Date of filing of the Form 4. |
Keywords
BioDeisx, BDSX, insider trading, Form 4, stock transaction, restricted stock units, Chris Vazquez, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.